3.15pm – 4pm BST, 16 October 2025 ‐ 45 mins
Panel and Q&A
The Deep Biotech revolution is here, and there are dozens of companies working on innovative solutions to some of society's biggest problems. However, in most cases scaling remains a challenge - so how can we build a mutually supportive ecosystem that will allow us to tackle this?


COO, Prokarium


Head of Microbial Engineering, Colorifix

Co-founder & CSO, SymphoRNA
Dr. Ruth Helen Faram is Co-founder and Chief Scientific Officer at SymphoRNA (previously Uncommon Bio), where she leads the R&D & scientific strategy including novel technologies and IP development in the field of RNA and drug delivery.
Ruth brings extensive years of experience in cell and molecular biology, working with cutting edge, innovative technologies. She holds a BSc. Neuroscience from University College London, MSc. Pharmacology from the University of Oxford and D.Phil in Anatomical Neuropharmacology from the University of Oxford, where she specialised in novel cell characterisation and stem cell technologies. She subsequently held three postdoctoral positions within the University of Oxford as part of Innovation Medicines Initiative for Stem Cells in Drug Discovery, also receiving scholarships from the Medical Research Council and Alzheimer’s Research UK, working with iPSCs following their discovery as a Nobel Prize winning technology in 2012.
She is inventor on 7 patents (pending). She is a mum to 6 year old Felix, and 1 year old Florence, and is a seasoned marathon runner & cyclist.

Co-founder and CEO, twig
Russ is co-founder and CEO at twig, a bioengineering start-up combining AI, robotics and biology, driving a global transition to bio-fermented ingredients in a way that benefits everyone – people, producers, and the planet.
In addition to twig, Russ co-founded and led cultivated meat pioneer Ivy Farm, a spin-out from the University of Oxford that created the first cultivated meat sausage and scotch egg, and has grown to a team of over 60.
Prior to starting companies, Russ worked as a management consultant at Boston Consulting Group. He holds a D.Phil. in Biomedical Engineering from Oxford, a Masters in Mechanical Engineering from Loughborough and is a Fellow Chartered Accountant.